JDD Author and Psoriasis Expert Andrew Blauvelt, MD, MBA: Watch His “Curing Psoriasis” Translational Lecture Series

See JDD author Dr. Andrew Blauvelt bring cutting‑edge psoriasis science to life in GWU’s Dermatology Translational Science Lecture Series, and learn about his new Nature study on high‑induction risankizumab dosing.

Congratulations to JDD author and psoriasis expert Andrew Blauvelt, MD, MBA, on his recent Nature article, “A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab.” The phase 2 KNOCKOUT (NCT05283135) study evaluated higher‑than‑approved induction doses of risankizumab and tracked clinical and tissue‑level responses for 100 weeks, finding high and durable skin clearance, marked reductions in lesional tissue‑resident memory T cells (TRM), and no new safety signals.

To learn more about this exciting work check out Dr. Blauvelt’s recent presentation at the George Washington University’s Dermatology Translational Science Lecture Series titled “Curing Psoriasis.” Click below to watch now!

Catch up on some of Dr. Blauvelt’s JDD psoriasis articles:

Long-Term Treatment Patterns Among Patients With Psoriasis Treated With Ixekizumab or Adalimumab: A Real-World Study 

Importance of Complete Skin Clearance in Psoriasis as a Treatment Goal: Implications for Patient-Reported Outcomes 

Essential Truths for the Care and Management of Moderate-to-Severe Psoriasis